Pandemic influenza virus vaccine - AlphaVax

Drug Profile

Pandemic influenza virus vaccine - AlphaVax

Alternative Names: H1N1 influenza vaccine - AlphaVax; H5N1 influenza vaccine - AlphaVax; Pandemic influenza vaccine (H1B and H5) - AlphaVax

Latest Information Update: 07 May 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator AlphaVax
  • Class Influenza A vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Phase I Influenza A virus H1N1 subtype; Influenza A virus H5N1 subtype

Most Recent Events

  • 07 May 2018 Phase-I clinical trials in Influenza-A virus H1N1 subtype in USA (Parenteral) (AlphaVax pipeline, May 2018)
  • 07 May 2018 Phase-I clinical trials in Influenza-A virus H5N1 subtype in USA (Parenteral) (AlphaVax pipeline, May 2018)
  • 16 Jul 2016 No recent reports of development identified for preclinical development in Influenza-A-virus-H1N1-subtype in USA (Parenteral)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top